Fact CheckerSign in

NCT07839221Not yet recruiting

Combined Growth Differentiation Factor-15 (GDF-15) and Lung Ultrasound for ILD Screening in Rheumatoid Arthritis and Systemic Sclerosis

Source: ClinicalTrials.gov · Last updated 25 Sept 2026

Brief summary (registry, in English)

The goal of this observational study is to detect the lung affection in patients with Rheumatoid Arthritis(RA) or Systemic sclerosis (SSc) before appearance of symptoms(Subclinical) using combined diagnostic modalities which are Lung Ultrasound and a blood marker called Growth Differentiation Factor-15 (GDF-15). The main question it aims to answer is: Does the combination of these 2 modalities have the diagnostic accuracy similar to the gold standard test which is High Resolution Computed Tomography (HRCT) of the Lungs? Does this combination have the potential to become a validated screening tool? Participants will be in 2 groups: the RA group and the SSc group, each will have the diagnostic combination and a reference HRCT for comparison of results.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
110 (estimated)
First submitted
19 Sept 2026
Start date
15 Oct 2026
Primary completion date
30 Oct 2028
Lead sponsor
Assiut University
NCT number
NCT07839221

What you commit to

  • Study type: Observational
  • Planned participants: 110
  • From 15 Oct 2026 to the primary completion date, 30 Oct 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Active respiratory tract infection or acute exacerbation of pulmonary disease.
  • Other causes of pulmonary fibrosis such as history of heavy smoking (\>15 pack-years) or significant environmental/occupational exposure known to induce pulmonary fibrosis.
  • Pre-existing primary chronic lung diseases (e.g., COPD, bronchial asthma, active tuberculosis, severe bronchiectasis).

Who the study is looking for

  • 1- Adult patients (≥18 years) with confirmed diagnosis of RA or SSc.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.